Novartis Expands Zolgensma Manufacturing Capacity With Approval Of Multi-Product North Carolina Facility
Novartis Announced The Us Food And Drug Administration (Fda) Has Granted Commercial Licensure Approval For Its Durham, North California Site, A Multi-Product Gene Therapy Manufacturing Facility. This Approval Allows The State-Of-The-Art, 170,000 Square-Foot Facility To Make, Test And Release Commercial Zolgensma, As Well As Produce Gene Therapy Product For Current And Future Clinical Trials.The Clearance Of This Milestone Brings Online The Second Commercially-Licensed Manufacturing Facility For Novartis Gene Therapies, Joining The Libertyville, Ill. Site, Which Was Approved For Zolgensma (Onasemnogene Abeparvovec) Manufacturing And Distribution In 2019. The Durham Site Will Build On Novartis Gene Therapies
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!